The IBD SmartSelect Composite Rating for Vertex Pharmaceuticals increased from 94 to 96 Monday.
The revised score means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength. The best stocks tend to have a 95 or better grade as they begin to launch a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch.
Vertex Pharmaceuticals is currently forming a consolidation, with a 519.88 buy point. See if the stock can break out in heavy trade at least 40% higher than normal.
Lean How — And When — To Sell Stocks
The stock earns an 80 EPS Rating, meaning its recent quarterly and annual earnings growth tops 80% of all stocks.
Its Accumulation/Distribution Rating of A shows heavy buying by institutional investors over the last 13 weeks.
The company reported a -5% rise in earnings for Q4. Revenue growth increased 16%, up from 12% in the prior report. The company has now posted increasing growth in each of the last two quarters.
Vertex Pharmaceuticals holds the No. 3 rank among its peers in the Medical-Biomed/Biotech industry group. Krystal Biotech is the top-ranked stock within the group.
